Skip to main content

Table 2 Frequency of anti-endothelial cell antibodies (AECA) and AECA titers in patients with Susac syndrome (SuS) and controls according to cut-off levels

From: Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study

 

AECA, patients (%)

 

AECA, samples (%)

 

AECA, median titers

AECA, titer ranges

 

AECA ≥1:10

     

Definite SuS

7/20 (35)

P = 0.036c,d

11/32 (34)

P = 0.012c,d

1:3200

1:100 – 1:17,500

Limited SuS

0/5 (0)

0/5 (0)

N.a.

N.a.

Controls

8/70 (11)

8/70 (11)

1:100

1:10 – 1:320

  HC

2/20 (10)

2/20 (10)

1:55

1:10 – 1:100

  MS

4a/25 (16)

4/25 (16)

1:210

1:10 – 1:320

  CTD

2b/25 (8)

2/25 (8)

1:165

1:10 – 1:320

 

AECA >1:100

     

Definite SuS

5/20 (25)

P = 0.015c,d

9/32 (28)

P = 0.002c,d

1:3200

1:100 – 1:17,500

Limited SuS

0/5 (0)

0/5 (0)

N.a.

N.a.

Controls

3/70 (4)

3/70 (4)

1:320

1:320 – 1:320

  HC

0/20 (0)

0/20 (0)

N.a.

N.a.

  MS

2/25 (8)

2/25 (8)

1:320

1:320 – 1:320

  CTD

1/25 (4)

1/25 (4)

1:320

1:320

 

AECA >1:320

     

Definite SuS

3/20 (15)

P = 0.01c,d

7/32 (22)

P < 0.0002c,d

1:7500

1:1000 – 1:17,500

Limited SuS

0/5 (0)

0/5 (0)

N.a.

N.a.

Controls

0/70 (0)

0/70 (0)

N.a.

N.a.

  HC

0/20 (0)

0/20 (0)

N.a.

N.a.

  MS

0/25 (0)

0/25 (0)

N.a.

N.a.

  CTD

0/25 (0)

0/25 (0)

N.a.

N.a.

  1. a3 × RRMS, 1 × PPMS. b1 × SLE, 1 × Sjögren syndrome. cFisher’s exact test. dDefinite SuS vs controls. N.a. = not applicable.